Irinotecan and Cisplatin for Advanced Pancreatic Cancer
Author Information
Author(s): Markham C, Stocken D D, Hassan A B
Primary Institution: University Hospital Birmingham NHS Trust
Hypothesis
Can the combination of irinotecan and cisplatin improve outcomes in patients with advanced pancreatic cancer?
Conclusion
The irinotecan and cisplatin combination showed limited effectiveness and significant toxicity in patients with advanced pancreatic cancer.
Supporting Evidence
- Only one patient had a partial response to treatment.
- The median overall survival was 5.0 months.
- Severe toxicity was observed, leading to the trial's early termination.
Takeaway
Doctors tested a new medicine for people with a serious type of cancer, but it didn't help much and made some people very sick.
Methodology
The study involved 19 chemotherapy-naïve patients with advanced pancreatic cancer, assessing the effects of irinotecan and cisplatin on survival and response rates.
Potential Biases
Patient selection may have biased results as only those with good performance status were included.
Limitations
The study had a small sample size and was terminated early due to toxicity concerns.
Participant Demographics
{"sex":{"male":8,"female":10},"age":{"median":61,"range":"38-74"},"performance_status":{"100":2,"90":12,"80":4},"site_of_disease":{"pancreatic_head":15,"body_and_tail":3},"stage_of_disease":{"IVA":6,"IVB":12}}
Statistical Information
Confidence Interval
{"overall_survival":"95% CI: 3.9, 10.1","progression_free_survival":"95% CI: 1.3, 3.7"}
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website